The non-invasive blood pressure monitoring product line includes MAXNIBP and MAXIQ™technology, which are supplied by CASMED through OEM agreements to various companies throughout the world. Sales of these products totaled $3.6 million in 2016 and $700,000 in the first quarter of 2017. Sales from CASMED’s continuing operations, excluding the non-invasive blood pressure products, were $18.7 million and $4.5 million, respectively, for those periods. FORE-SIGHT disposable sensor sales comprised more than 85 percent of the revised total net sales from operations during each of those periods.
The company will reclassify the non-invasive blood pressure monitoring results to discontinued operations when it reports its overall financial results for the second quarter and six months ended June 30, 2017, and 2016.
“With the divestiture of these final non-core legacy assets, we can now direct full attention to our FORE-SIGHT tissue oximetry products and use proceeds from this transaction to support our ongoing growth initiatives,” said Thomas M. Patton, president and CEO of CASMED. “We estimate the worldwide cerebral oximetry market will ultimately reach $800 million annually and, given the accuracy and reliable readings from our FORE-SIGHT tissue oximeter, believe we are in an excellent competitive position.”
SunTech is the world’s largest supplier of OEM advanced blood pressure monitoring products and technology for customers and patients.
“This proprietary non-invasive blood pressure product line has the ability to accurately and reliably produce measurement results in high-motion environments and rounds out our product offering,” said Robert Sweitzer, president of SunTech. “This is an important advantage especially in the most challenging clinical situations where measurements can be difficult to obtain, making this product line an ideal fit for SunTech and our worldwide customer base.”
CASMED FORE-SIGHT Cerebral Oximeters provide a highly accurate, non-invasive measurement of tissue oxygenation in the brain. Direct monitoring of tissue oxygenation can provide a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygen in the brain and empower them to improve patient care.